Recently, tazemetostat, a methyltransferase inhibitor, has been approved by FDA for relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and who have received at least 2 prior systemic therapies and also for relapsed or refractory follicular lymphoma who have no suitable alternative treatment options [222]. Here, EZH2 is linked to follicular lymphoma.